Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.50 |
| ▸ | AURKA | O14965 | 9/20 | 0.48 |
| ▸ | TEK | Q02763 | 9/20 | 0.48 |
| ▸ | MET | P08581 | 8/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.48 |
| ▸ | LCK | P06239 | 6/20 | 0.48 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272701 | 0.89 | KDR (0.50) | KDRAURKATEKMETAURKB | |
| SCHEMBL273636 | 0.84 | KDR (0.53) | KDRAURKATEKMETAURKB | |
| SCHEMBL3595046 | 0.80 | KDR (0.51) | KDRAURKATEKMETAURKB | |
| SCHEMBL3582067 | 0.78 | KDR (0.53) | KDRAURKATEKMETAURKB | |
| SCHEMBL274874 | 0.78 | PDE4B (0.54) | KDRAURKATEKMETAURKB | |
| SCHEMBL22048761 | 0.77 | KDR (0.55) | KDRAURKATEKMETAURKB | |
| SCHEMBL279238 | 0.76 | KDR (0.70) | KDRFLT1RET | |
| SCHEMBL2466583 | 0.75 | KDR (0.69) | KDRAURKATEKMETAURKB | |
| SCHEMBL2468881 | 0.75 | KDR (0.68) | KDRAURKATEKMETAURKB | |
| SCHEMBL274382 | 0.74 | KDR (0.53) | KDRAURKATEKMETAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2371822-A1 | Heterobicyclic carboxamides as inhibitors for kinases | Novartis AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | KDR 3083/4885AURKA 2811/4885TEK 3457/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | KDR 1319/4885AURKA 343/4885TEK 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.